The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Samartcev I.N.

Kirov Military Medical Academy

Zhivolupov S.A.

Kirov Military medical academy

Contemporary concepts of the rational use of centrally acting skeletal muscle relaxants in the treatment of vertebrogenic dorsalgia

Authors:

Samartcev I.N., Zhivolupov S.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(12): 154‑160

DOI: 10.17116/jnevro2025125121154

Read: 441 times

Buy for 300₽
Contact the author
Table of contents

CONTEMPORARY CONCEPTS OF THE RATIONAL USE OF CENTRALLY ACTING SKELETAL MUSCLE RELAXANTS IN THE TREATMENT OF VERTEBROGENIC DORSALGIA
CONTEMPORARY CONCEPTS OF THE RATIONAL USE OF CENTRALLY ACTING SKELETAL MUSCLE RELAXANTS IN THE TREATMENT OF VERTEBROGENIC DORSALGIA

To cite this article:

Samartcev IN, Zhivolupov SA. Contemporary concepts of the rational use of centrally acting skeletal muscle relaxants in the treatment of vertebrogenic dorsalgia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(12):154‑160. (In Russ.)
https://doi.org/10.17116/jnevro2025125121154

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Recommended articles:
Effe­ctiveness and tole­rability of agomelatine (Valdoxan) in the treatment of depression after COVID-19 (TELESFOR study). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(9):90-98
Asso­ciations of poly­morphic variants of CYP2C19*2, *17 with effe­ctiveness and safety of sertraline in adolescents with a depressive episode and suicidal tendencies. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(10-2):12-20
Onasemnogene abeparvovec gene replacement therapy for spinal muscular atro­phy in children: a Moscow expe­rience. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(10-2):103-113
An open-label obse­rvational study of the effi­cacy and tole­rability of rapi­dly dissolving forms of aceclofenac and nime­sulide for oral use in the treatment of patients with acute non-specific low back pain (ASTRA study). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(12):141-147
Comparative analysis of the effe­ctiveness of modern physiotherapeutical methods of dorsalgia treatment. Problems of Balneology, Physiotherapy and Exercise Therapy. 2025;(2):35-44
Expe­rience of using ribo­ciclib in the therapy of meta­static breast cancer in a regional onco­logical dispensary. P.A. Herzen Journal of Onco­logy. 2025;(3):89-93
Reso­lution of the exte­nded meeting of the Presidium and committees of the Russian Asso­ciation for the Study of Pain (RASP) “The role of central muscle rela­xants in the treatment of non-specific low back pain”. Russian Journal of Pain. 2025;(2):91-91
Costs of home-based respiratory support and oxygen therapy. Medi­cal Technologies. Asse­ssment and Choice. 2025;(3):93-102
Resu­lts of manual therapy in dege­nerative spine diseases with and without radi­culopathy. (Literature review). Problems of Balneology, Physiotherapy and Exercise Therapy. 2025;(4):47-55
Abstract:

Centrally acting skeletal muscle relaxants (CMs) in combination with nonsteroidal anti-inflammatory drugs and vitamins B are among the most frequently prescribed medications for the treatment of dorsalgia. Despite belonging to the same clinical and pharmacological group, CMs differ from each other in both their mechanism of action and the range of adverse effects. The emergence of new CMs in clinical practice demonstrates the growing innovation of this class of pharmacological agents in the treatment of musculoskeletal pain, necessitating a detailed study of the competitive advantages of individual CMs to improve treatment efficacy and safety.

Keywords:

dorsalgia
centrally acting skeletal muscle relaxants
efficacy
tolerability

Authors:

Samartcev I.N.

Kirov Military Medical Academy

Zhivolupov S.A.

Kirov Military medical academy

Received:

14.10.2025

Accepted:

20.10.2025

Close metadata

References:

  1. Pain syndromes in neurological practice. A.M. Vein. M.: MEDpress-info; 2001. 368 p. (In Russ.).
  2. Yahno NN, Kukushkin ML, Churyukanov MV, Syrovegin AV. The results of open multicentral study «MERIDIAN» for assessment of pain syndromes prevalence in ambulatory and therapeutic preferences of physicians. Russian Journal of Pain. 2012;3(36-37):10-14. (In Russ.).
  3. Browning R., Jackson J.L., O’Malley P.G. Cyclobenzaprine and back pain: a meta-analysis. Arch Intern Med. 2001;161(13):1613-1620. https://doi.org/10.1001/archinte.161.13.1613
  4. https://cr.minzdrav.gov.ru/schema/778_1  https://cr.minzdrav.gov.ru/schema/778_1
  5. https://cr.minzdrav.gov.ru/preview-cr/777_1  https://cr.minzdrav.gov.ru/preview-cr/777_1
  6. https://cr.minzdrav.gov.ru/preview-cr/826_1. https://cr.minzdrav.gov.ru/preview-cr/826_1.
  7. Oliveira C, Maher C, Pinto R, et al. Clinical practice guidelines for the management of non-specific low back pain in primary care: an updated overview. Eur Spine J. 2018;27(11):2791-2803. https://doi.org/10.1007/s00586-018-5673-2
  8. Van Tulder M, Touray T, Furlan A, et al. Muscle relaxants for nonspecific low back pain: A systematic review within the framework of the Cochrane Collaboration. Spine. 2003;28(17):1978-1992.
  9. Cashin A, Wand B, O’Connell N, et al. Pharmacological treatments for low back pain in adults: an overview of Cochrane Reviews. Cochrane Database Syst Rev. 2023;4;4(4):CD013815. https://doi.org/10.1002/14651858
  10. Manca A, Cugusi L, van Tulder, M, et al. Oral non-benzodiazepine muscle-relaxants for people with acute and chronic primary low back pain: a systematic review with meta-analysis. Eur Spine J. 2025;34;2347-2366. https://doi.org/10.1007/s00586-025-08786-0
  11. Tekes K. Basic aspects of the pharmacodynamics of tolperisone, a widely applicable centrally acting muscle relaxant. Open Med Chem J. 2014;8:17-22.  https://doi.org/10.2174/1874104501408010017
  12. Ovchinnikova EA, Rashid MA, Kulikov AYu, et al. Efficacy, safety and pharmacoeconomical aspects of tolperizone use. Practice. 2005;1:1-9. (In Russ.).
  13. Abranyi I. Study on the effect of 150-mg Mydocalm coated tablets in peripheral vascular diseases and in myotonias of various origin. Hung Med J. 1988;36(2):56-61. 
  14. Kukushkin ML. Tolperisone: mechanism of action, clinical efficacy and safety in the treatment of musculoskeletal pain. Russian Journal of Pain. 2022;20(2):63-67. (In Russ.). https://doi.org/10.17116/pain20222002163
  15. Devlikamova FI. Results of the post-registration study “PARUS” to assess the efficacy and safety of the drug Midocalm-Richter in local injection therapy of the myofascial trigger zone. Therapeutic Archive. 2018;6:81-88. (In Russ.).
  16. Samartcev IN, Zhivolupov SA, Parshin MS, Magomedov KR. The efficacy and tolerability of tolperisone hydrochloride various regimens in the treatment of patients with acute musculoskeletal low back pain. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(9):60-67. (In Russ.). https://doi.org/10.17116/jnevro202412409160
  17. Dulin J, Kovacs L, Ramm S, et al. Evaluation of sedative effects of single repeated doses of 50 mg and 150 mg Tolperisone Hydrochloride. Results of prospective, randomized, double-blind, placebo-control trial. Pharmacopsychiatry. 1998;31(4):136-142.  https://doi.org/10.1055/s-2007-979315
  18. Witenko C, Moorman-Li R, Motycka C, et al. Considerations for the appropriate use of skeletal muscle relaxants for the management of acute low back pain. Pharm Ther. 2014;39(6):427-435. 
  19. Karoln D, Muzyk A, Preud’homme X. A case of delirium, motor disturbance, and autonomic dysfunction due to baclofen and tizanidine withdrawal: a review of the literature. Gen Hosp Psychiatry. 2011;33(1):84.e1-2.  https://doi.org/10.1016/j.genhosppsych.2010.10.003
  20. Kaddar N, Vigneault P, Pilote S, et al. Tizanidine (Zanaflex): a muscle relaxant that may prolong the QT interval by blocking IKr. J Cardiovasc Pharmacol Ther. 2012;17(1):102-9.  https://doi.org/10.1177/1074248410395020
  21. Kobayashi H, Hasegawa Y, Ono H. Cyclobenzaprine, a centrally acting muscle relaxant, acts on descending serotonergic systems. Eur J Pharm. 1996;311(1):29-35.  https://doi.org/10.1016/0014-2999(96)00402-5
  22. Huang Z, Ung T. Effect of alpha-1-acid glycoprotein binding on pharmacokinetics and pharmacodynamics. Curr Drug Metab. 2013;14(2):226-238. 
  23. Braschi E, Garrison S, Allan G. Cyclobenzaprine for acute back pain. Can Fam Physician. 2015;61(12):1074.
  24. Carette S, Bell M, Reynolds W, et al. Comparisons of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia. A randomized, double-blind clinical trial. Arthritis Rheum. 1994;37(1):32-40.  https://doi.org/10.1002/art.1780370106
  25. Chou R, Peterson K, Helfand M. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. J Pain Symptom Manage. 2004;28(2):140-175.  https://doi.org/10.1016/j.jpainsymman.2004.05.002
  26. Landy S, Altman C, Xie F. Time to recovery in patients with acute painful musculoskeletal conditions treated with extended-release or immediate-release cyclobenzaprine. Adv Ther. 2011;28(4):295-303.  https://doi.org/10.1007/s12325-011-0008-2
  27. Douglass M, Levine D. Hallucinations in an elderly patient taking recommended doses of cyclobenzaprine. Arch Intern Med. 2000;160(9):1373. https://doi.org/10.1001/archinte.160.9.1373
  28. Okada M, Nose T. Eperisone Hydrochloride, a Muscle Relaxant, Is a Potent P2X7 Receptor Antagonist. Chem Pharm Bull (Tokyo). 2024;72(3):345-348.  https://doi.org/10.1248/cpb.c24-00032
  29. Sakai Y, Matsuyama Y, Nakamura H, et al. The effect of muscle relaxant on the paraspinal muscle blood flow: A randomized controlled trial in patients with chronic low back pain. Spine (Phila Pa 1976). 2008;33(6):581-587.  https://doi.org/10.1097/BRS.0b013e318166e051
  30. Bresolin N, Zucca C, Pecori A. Efficacy and tolerability of eperisone and baclofen in spastic palsy: A double-blind randomized trial. Adv Ther. 2009;26:563-573.  https://doi.org/10.1007/s12325-009-0031-8
  31. Sartini S, Guerra L. Open experience with a new myorelaxant agent for low back pain. Adv Ther. 2008;25:1010-8.  https://doi.org/10.1007/s12325-008-0108-9
  32. Zhu J, Xiao J, Hu J, et al. Muscle Strength Decline Caused by Eperisone Hydrochloride: A Case Report. Clin Ther. 2024;46(1):74-78.  https://doi.org/10.1016/j.clinthera.2023.10.003
  33. Nielsen R, Fomsgaard J, Siegel H, et al. The effect of chlorzoxazone on acute pain after spine surgery. A randomized, blinded trial. Acta Anaesthesiol Scand. 2016;60(8):1152-60.  https://doi.org/10.1111/aas.12754
  34. Kornhuber J, Parsons C, Hartmann S et al. Orphenadrine is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist: binding and patch clamp studies. J Neural Transm Gen Sect. 1995;102(3):237-246.  https://doi.org/10.1007/BF01281158
  35. Desaphy J, Dipalma A, De Bellis M, et al. Involvement of voltage-gated sodium channels blockade in the analgesic effects of orphenadrine. Pain. 2009;142(3):225-235.  https://doi.org/10.1016/j.pain.2009.01.010
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.